


PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4981993

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	INNORA GMBH	05/14/2018
RECEIVING PARTY DATA		
Name:	QUATTRO VASCULAR PTE LTD	
Street Address:	2 SHENTON WAY	
Internal Address:	18-01 SGX CENTRE 1	
City:	SINGAPORE	
State/Country:	SINGAPORE	
Postal Code:	068804	
PROPERTY NUMBERS Total: 2		
	Property Type	Number
	Application Number:	61547448
	Patent Number:	9415140
CORRESPONDENCE DATA		
Fax Number:	(949)760-9502	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	949-760-0404	
Email:	ldo@kmob.com	
Correspondent Name:	KNOBBE, MARTENS, OLSON & BEAR, LLP	
Address Line 1:	2040 MAIN STREET, 14TH FLOOR	
Address Line 4:	IRVINE, CALIFORNIA 92614	
ATTORNEY DOCKET NUMBER:	QTRO.000GEN	
NAME OF SUBMITTER:	SHANNON LAM	
SIGNATURE:	/Shannon Lam/	
DATE SIGNED:	05/29/2018	
Total Attachments: 14		
source=Assignment#page1.tif		
source=Assignment#page2.tif		
source=Assignment#page3.tif		
source=Assignment#page4.tif		

source=Assignment#page5.tif
source=Assignment#page6.tif
source=Assignment#page7.tif
source=Assignment#page8.tif
source=Assignment#page9.tif
source=Assignment#page10.tif
source=Assignment#page11.tif
source=Assignment#page12.tif
source=Assignment#page13.tif
source=Assignment#page14.tif



PATENT ASSIGNMENT CONFIRMATORY AGREEMENT

This PATENT ASSIGNMENT CONFIRMATORY AGREEMENT (this "Agreement") is entered into on the 4th day of May, 2018 (the "Effective Date"), by and between TRIREME SINGAPORE PTE LTD and its affiliate QUATTRO VASCULAR PTE LTD with its principal place of business at 2 Shenton Way, #18-01 SGX Centre 1, Singapore 068804 (collectively, "TriReme"), and INNORA GMBH with its principal place of business at Robert-Koch-Platz 4, 10115 Berlin, Germany ("InnoRa"). TriReme and InnoRa are each referred to herein by name, or individually, as a "Party" or, collectively, as the "Parties."

BACKGROUND

- A. The Parties entered into that certain Development and License Agreement effective as of April 3, 2011 (the "Development Agreement"), pursuant to which TriReme retained the services of InnoRa to develop technologies for the application and incorporation of the InnoRa Technology with and into TriReme's products as further described in the Development Agreement.
- B. In accordance with Section 6.1.2 of the Development Agreement, TriReme owns all right, title, and interest, including all intellectual property rights, in and to any and all Development Technology (as defined in the Development Agreement), whether developed solely by TriReme or InnoRa or jointly by both of them, and InnoRa assigned all such right, title, and interest to TriReme and agreed to execute further documents and perform further acts as requested by TriReme in order to confirm TriReme's rights in such Development Technology.
- C. InnoRa developed certain technologies pursuant to the Development Agreement that qualify as Development Technology, and InnoRa filed and prosecuted at its own cost the patents identified in Exhibit A covering such technologies.

NOW, THEREFORE, in consideration of the mutual covenants and agreements provided herein below and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ARTICLE 1 TRANSFER OF PATENT RIGHTS

1.1 Assignment of Patents. Per the request of TriReme, InnoRa hereby assigns, transfers, and conveys to Quattro Vascular Pte Ltd in perpetuity all right, title, and interest, including all intellectual property rights, now or hereafter existing throughout the world in and to the patents and applications identified in Exhibit A (collectively, the "Identified Patents"), together with (all such rights together with the Identified patents, collectively, the "Patent Rights"), in each case to the extent not already assigned to TriReme by virtue of Section 6.1.2 of the Development Agreement:

- (a) all patents and patent applications (i) to which any of the Identified Patents directly or indirectly claims priority and (ii) for which any of the Identified Patents directly or indirectly forms a basis for priority, in either case to the extent owned or controlled by InnoRa as of the Effective Date;
- (b) all provisionals, reissues, reexaminations, extensions, continuations, continuations in part, continuing prosecution applications, requests for continuing examinations, divisionals, and registrations of any of the Identified Patents and/or any item in the foregoing category (a);

- (c) all foreign counterpart patents and foreign counterpart patent applications relating to the Identified Patents and/or any item in any of the foregoing categories (a) through (b), including without limitation certificates of invention, utility models, industrial design protection, design patent protection, and any other governmental grants or issuances;
- (d) all inventions, invention disclosures, designs, and discoveries disclosed or claimed in the Identified Patents and/or any item in any of the foregoing categories (a) through (c);
- (e) all right, title, and interest InnoRa acquired in the Identified Patents and/or any item in any of the foregoing categories (a) through (d) by way of any agreements assigning ownership of any of the foregoing from the inventors and/or prior owners to InnoRa;
- (f) all rights to apply in any or all countries of the world for patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any of the Identified Patents and/or any item in any of the foregoing categories (a) through (e), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other similar convention, treaty, agreement, or understanding;
- (g) for any Identified Patent or other item identified herein terminally disclaimed to another patent or patent application, all patents and patent applications subject to any such terminal disclaimer and owned or controlled by InnoRa as of the Effective Date;
- (h) all patents that issue from any of the Identified Patents and/or any item in any of the foregoing categories (a) through (g);
- (i) all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and all other enforcement rights under, or on account of, any of the Identified Patents and/or any item in any of the foregoing categories (a) through (h), including, without limitation, all causes of action and other enforcement rights for (i) damages (past, current, and future), (ii) injunctive relief, and (iii) any other remedies of any kind for past, current, and future infringement, including all rights afforded under 35 U.S.C. § 154(d); and
- (j) all rights to collect royalties and other payments under or on account of any of the Identified Patents and/or any item in any of the foregoing categories (a) through (i).

1.2 Assignment Recordation. On the Effective Date, InnoRa shall execute and deliver to TriReme the Patent Assignment in the form set forth in Exhibit B (the "Patent Assignment"). To the extent the Patent Rights include any non-U.S. patents and/or patent applications, InnoRa will deliver to TriReme executed documents in a form provided by TriReme as may be required in the non-U.S. jurisdiction in order to perfect the assignment to TriReme of the non-U.S. patents and/or patent applications. However, TriReme agrees not to record such Patent Assignment at the PTO or any other relevant patent office unless and until that certain Asset Purchase and Option Agreement by and among QT Vascular Ltd., Trireme Medical, LLC, Quattro Vascular Pte. Ltd., Trireme Medical (Singapore) Pte. Ltd., Teleflex Life Sciences Unlimited Company, Teleflex Incorporated, and the Non-Compete Parties (as defined therein) (the "APA") is fully executed by the parties thereto (the "APA Signing Date") or InnoRa otherwise gives TriReme consent to record the assignment. TriReme shall provide written notice to InnoRa of the occurrence of the APA Signing Date.

ARTICLE 2 PATENT FEES AND PAYMENT

2.1 Patent Fees and Patent Application and Prosecution Expenses. InnoRa shall pay all registration, filing, maintenance, issuance, and other similar fees and costs required to be paid for the prosecution and maintenance of the Identified Patents and other Patent Rights prior to the Effective Date. Within fifteen (15) days of the Effective Date, InnoRa shall provide to TriReme a detailed accounting of all necessary registration, maintenance, issuance, renewal, and other relevant filing expenses paid by InnoRa prior to the Effective Date for the purposes of prosecuting or maintaining the Patent Rights, and such accounting shall include a description of the applicable cost, the applicable patent, the applicable jurisdiction, the date such fee was due, and the date such fee was paid. The lesser of such amount or €80,000 is the "Patent Fees." In addition, within fifteen (15) days of the Effective Date, InnoRa shall also provide an accounting of all relevant filing fees for the Patent Rights to be paid during the period beginning on the Effective Date and ending ninety (90) days thereafter, which shall include a description of the applicable fee, the applicable patent, the applicable jurisdiction, and the date such fee is due.

2.2 Payment. Within thirty (30) days of provision of the accounting for the Patent Fees described in Section 2.1, TriReme shall pay InnoRa the Patent Fees. InnoRa agrees that TriReme shall not be responsible for, nor pay InnoRa, any taxes, fees, or any other amounts in excess of the Patent Fees.

ARTICLE 3 ADDITIONAL OBLIGATIONS

3.1 Transmittal of Documents. Within ten (10) days of the Effective Date, InnoRa shall send to TriReme: (a) all agreements assigning ownership of the Patent Rights from the inventors and/or prior owners to InnoRa; (b) InnoRa's patent counsel's reasonably current list (or other means of tracking information) relating to the prosecution or maintenance of the Patent Rights throughout the world, including without limitation the names and contact information of other prosecution counsel and agents involved in the prosecution and maintenance of the Patent Rights, and information relating to deadlines, payments, and filings for the Patent Rights; (c) conception and reduction to practice materials disclosed in each patent case which were created on or before the date of the earliest priority claim for the Patent Rights; (d) all files, documents, and tangible things constituting, comprising, or relating to the investigation, evaluation, preparation, prosecution, maintenance, defense, filing, issuance, or registration of each of the Patent Rights (the "Prosecution History Files"); (e) the original ribbon copy or government issued certificate for each patent or application included in the Patent Rights; and (f) an identification of each patent family included in the Patent Rights, where each family is identified by the parent patent or application in the family that has the earliest filing date. InnoRa acknowledges and agrees that TriReme may request, and InnoRa shall provide, additional documents, if any such provided documentation does not appear complete.

3.2 Further Cooperation. At the request of TriReme, InnoRa shall execute and deliver such other instruments and do and perform such other lawful acts as may be reasonably necessary for effecting completely the consummation of the transactions contemplated hereby, including without limitation execution, acknowledgment, and recordation of other such papers, and obtaining the same from the respective inventors, as necessary for fully perfecting and conveying unto TriReme the benefit of the transactions contemplated hereby. InnoRa hereby grants TriReme power of attorney to (a) execute documents in the name of InnoRa that InnoRa declines to execute, solely as necessary in order to effectuate the recordation of the transfers of any portion of the Patent Rights in any governmental filing office; and (b) instruct legal counsel to take steps to pay maintenance fees and annuities that InnoRa declines to pay and to make filings on behalf of InnoRa prior to the APA Signing Date solely as necessary to preserve the Patent Rights through such date. To the extent any attorney-client privilege or the attorney work-product doctrine applies to any portion of the Prosecution History Files, and such portion of the Prosecution History Files remains under InnoRa's possession or control, InnoRa shall not disclose

the same to any third party unless (i) disclosure is ordered by a court of competent jurisdiction, after all appropriate appeals to prevent disclosure have been exhausted; and (ii) InnoRa gives TriReme prompt notice upon learning that any third party sought or intended to seek a court order requiring the disclosure of any such portion of the Prosecution History Files.

3.3 Confidentiality. Each Party agrees to keep confidential and not publish or otherwise disclose or use any Confidential Information (as defined in the Development Agreement) related to this Agreement in accordance with Section 7 of the Development Agreement. Each Party acknowledges and agrees that the terms of this Agreement shall be deemed to be the Confidential Information of both Parties, except that TriReme may disclose this Agreement in confidence to the other parties to the APA for their due diligence purposes.

ARTICLE 4 REPRESENTATIONS AND WARRANTIES

InnoRa represents and warrants to TriReme:

4.1 General. InnoRa is duly organized and validly existing under the laws of its jurisdiction of incorporation and it has full right, power, authority, and capacity, and has taken all corporate and other action necessary to enter into and perform this Agreement. This Agreement is a legal and valid obligation binding upon InnoRa and enforceable against it in accordance with its terms. The execution, delivery, and performance of this Agreement by InnoRa does not conflict with any agreement, instrument, or understanding, oral or written, by which it is bound, nor, to its knowledge, violate any Law (as defined in the Development Agreement).

4.2 Title and Contest. InnoRa owns all right, title, and interest in and to the Patent Rights, including without limitation all right, title, and interest to sue for infringement of the Patent Rights. The Patent Rights are free and clear of any restrictions, liens, claims, mortgages, security interests, licenses, covenants not to sue, options, or other third party rights or encumbrances. There are and have been no actions, suits, investigations, claims, inter partes review proceedings, or any other proceedings of any nature threatened, pending, or in progress relating in any way to the Patent Rights. Upon the Effective Date, none of InnoRa, any inventor, or any third party will retain any rights or interest in the Patent Rights.

4.3 Validity and Enforceability. To the best of InnoRa's knowledge, all of the Patent Rights are valid and enforceable. If any of the Patents are terminally disclaimed (i.e., US9415140) to another patent or patent application, all patents and patent applications that are currently owned by InnoRa and subject to such terminal disclaimer are included in the patents and patent applications listed on Exhibit A. As of the Effective Date, none of the Patent Rights have expired, lapsed, been abandoned, or been deemed withdrawn. All annuity and maintenance fees that are necessary in order to keep the Patent Rights in force as of the Effective Date have been timely paid by InnoRa.

4.4 Conduct. None of InnoRa, its officers and directors, or any attorneys, agents, or representatives of the foregoing, have intentionally engaged in any conduct, nor intentionally omitted to perform any necessary act, the result of which would invalidate any of the Patent Rights or hinder their enforcement, including without limitation misrepresenting any Patent Rights to a government agency or standard-setting organization. InnoRa is not aware of any obligations imposed by a standards-setting organization on InnoRa to license any of the Patent Rights on particular terms or conditions.

4.5 Consents. Other than the filing of the recordings described in Section 1.2 above, no third party consent, notice, filing, or authorization is required to be made or obtained in connection with the execution, delivery, and performance of this Agreement by InnoRa.

ARTICLE 5 MISCELLANEOUS

5.1 Dispute Resolution. The Parties agree to resolve all disputes, controversies, or claims as to matters arising from or relating to this Agreement in accordance with Article 10 and Section 11.1 of the Development Agreement.

5.2 Entire Agreement/Modification. This Agreement, including its Exhibits, together with the Development Agreement, sets forth all the covenants, promises, agreements, warranties, representations, conditions, and understandings between the Parties with respect to the subject matter hereof and supersedes and terminates all prior agreements and understandings between the Parties with respect to such subject matter. No subsequent alteration, amendment, change, or addition to this Agreement shall be binding upon the Parties unless reduced to writing and signed by the respective authorized officers of the Parties.

5.3 Waiver. Nothing in this Agreement shall constitute a waiver of any right of, or excuse of any failure to perform any obligation of, a Party.

5.4 Additional Terms. The Parties acknowledge and agree that Sections 11.2, 11.4, 11.5, 11.6, 11.9, and 11.12 - 11.15 of the Development Agreement are incorporated herein by this reference and shall apply to this Agreement as if they had been expressly included herein.

IN WITNESS WHEREOF, the Parties have executed this Patent Assignment Confirmatory Agreement in duplicate originals by their duly authorized representatives as of the Effective Date.

TRIEME SINGAPORE PTE LTD

By: [Signature]

Name: Ertan Konstantino

Title: CEO

Date: May 25, 2018

INNORA GMBH

By: [Signature]

Name: Dr. Thomas Speck

Title: Director / Geschäftsführer

Date: 2018.05.14 / 14. Mai 2018

QUATTRO VASCULAR PTE LTD

By: [Signature]

Name: Lim May Ong

Title: Director

Date: May 25, 2018

Exhibit A

PATENTS

Patent No.	Country	Filing Date	Application No.	Issue Date	Title
	US	October 14, 2011	61/547,448		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	PCT	October 11, 2012	PCT/EP2012/070142		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
9,415,140 B2	US	October 11, 2012	14/350,483	August 16, 2016	FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
EP2766062 B1	EU	October 11, 2012	EP20120778272	August 26, 2015	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
CN104039371B	China	October 11, 2012	CN201280061266	June 1, 2016	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
ES2550348 (T3)	Spain	October 11, 2012	ES12778272T	June 11, 2015	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	Japan	October 11, 2012	JP2014535073A		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	Singapore	October 11, 2012	11201401329V	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
IT 50 2015 0000 76755	Italy	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
GB 2 766 062	United Kingdom	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
FR 2 766 062	France	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
DE 60 2012 010 093	Germany	October 11, 2012	EP20120778272	granted	VERBESSERTE FORMULIERUNGEN FÜR WIRKSTOFFBESCHICHTETE MEDIZINISCHE VORRICHTUNGEN

Exhibit B

PATENT ASSIGNMENT

This Patent Assignment (this "Assignment"), is made effective as of May 4th, 2018, by and between INNORA GMBH ("Assignor"), and QUATTRO VASCULAR PTE LTD ("Assignee").

WHEREAS, Assignor is the owner of record of the issued patents and/or patent applications set forth on Exhibit A attached hereto; and

WHEREAS, Assignor and Assignee have entered into that certain Patent Assignment Confirmatory Agreement, dated of even date herewith (as it may be amended, supplemented, or modified from time to time, the "Agreement"), under which, among other things, Assignor agreed to transfer to Assignee all of Assignor's right, title, and interest in and to all of its issued patents and patent applications set forth on Exhibit A (the "Identified Patents");

NOW, THEREFORE, in consideration of the mutual covenants, conditions, and agreements set forth herein and in the Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows:

1. Assignment. Assignor hereby assigns, transfers, and conveys to Assignee in perpetuity, and Assignee hereby accepts, any and all right, title, and interest, whether now or hereafter existing, in and to the Identified Patents. As part of such assignment, Assignor assigns, transfers, and conveys to Assignee, for Assignee's own use and enjoyment and for the use and enjoyment of Assignee's successors, assigns, and other legal representatives, as fully as the same would have been held and enjoyed by Assignor if this Assignment had not been made, the following:

- (a) all patents and patent applications (i) to which any of the Identified Patents directly or indirectly claims priority and (ii) for which any of the Identified Patents directly or indirectly forms a basis for priority, in each case to the extent owned or controlled by Assignor as of the date hereof;
- (b) all provisionals, reissues, reexaminations, extensions, continuations, continuations in part, continuing prosecution applications, requests for continuing examinations, divisionals, and registrations of any of the Identified Patents and/or any item in the foregoing category (a);
- (c) all foreign counterpart patents and foreign counterpart patent applications relating to the Identified Patents and/or any item in any of the foregoing categories (a) through (b), including without limitation certificates of invention, utility models, industrial design protection, design patent protection, and any other governmental grants or issuances;
- (d) all inventions, invention disclosures, designs, and discoveries disclosed or claimed in the Identified Patents and/or any item in any of the foregoing categories (a) through (c);
- (e) all right, title, and interest Assignor acquired in the Identified Patents and/or any item in any of the foregoing categories (a) through (d) by way of any agreements assigning ownership of any of the foregoing from the inventors and/or prior owners to Assignor;
- (f) all rights to apply in any or all countries of the world for patents, certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any of the Identified Patents and/or any item in any of the foregoing categories (a) through (e), including, without

limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other similar convention, treaty, agreement, or understanding;

- (g) for any Identified Patent or other item identified herein terminally disclaimed to another patent or patent application, all patents and patent applications owned or controlled by Assignor and subject to any such terminal disclaimer;
- (h) all patents that issue from any of the Identified Patents and/or any item in any of the foregoing categories (a) through (g);
- (i) all of Assignor's right, title, and interest to all causes of action (whether known or unknown or whether currently pending, filed, or otherwise) and all other enforcement rights under, or on account of, any of the Identified Patents and/or any item in any of the foregoing categories (a) through (h), including, without limitation, all causes of action and other enforcement rights for (i) damages (past, current, and future), (ii) injunctive relief, and (iii) any other remedies of any kind for past, current, and future infringement, including all rights afforded under 35 U.S.C. § 154(d); and
- (j) all rights to collect royalties and other payments under or on account of any of the Identified Patents and/or any item in any of the foregoing categories (a) through (i) pursuant to any agreements entered into between Assignor and any third party.

2. Recordation. Assignor hereby authorizes the Commissioner for Patents in the United States Patent and Trademark Office, and the corresponding entities or agencies in each applicable foreign country or multinational authority, to: (a) record Assignee as the assignee and owner of the entire interest in the Identified Patents or other rights identified in this Assignment; (b) deliver to Assignee, and to Assignee's attorneys, agents, successors, or assigns, all official documents and communications as may be warranted by this Assignment; and (c) issue any and all patents, certificates of invention, utility models, or other governmental grants or issuances that may be granted upon any of the Identified Patents or other rights identified in this Assignment in the name of Assignee, as the assignee to the entire interest therein.

3. Confirmatory Agreement. Nothing herein shall be deemed to extend or amplify the rights, remedies, duties, and obligations of Assignee or Assignor under the Agreement and, to the extent that there is any conflict between the terms and conditions of this Assignment and the terms and conditions of the Agreement, the terms and conditions of the Agreement shall govern, supersede, and prevail. Except as otherwise provided herein, all capitalized terms used and not defined herein (including the recitals hereto) shall have the respective meanings assigned to such terms in the Agreement.

4. Miscellaneous.

(a) Headings. The headings contained in this Assignment are intended solely for convenience and shall not affect the rights of the parties to this Assignment.

(b) Governing Law. This Assignment and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the Laws of the State of California, USA, without reference to conflict of laws principles.

(c) Counterparts and Facsimile Signatures. This Assignment may be executed in any number of counterparts, each of which shall be deemed an original, and all of which together, shall constitute one and the same instrument. Delivery of an executed counterpart of this Assignment by

transmission or by electronic mail in portable document format (.pdf) shall be as effective as delivery of a manually executed counterpart hereof.

(d) Amendments. No subsequent alteration, amendment, change, or addition to this Assignment shall be binding upon the parties unless reduced to writing and signed by the respective authorized officers of the parties.

(e) Successors and Assigns. This Assignment is executed by, shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.

IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Assignment as of the date first written above.

ASSIGNOR:

INNORA GMBH

By: Thomas Speck

Name: Dr. Thomas Speck

Title: Director / Geschäftsführer

Date: 2018.05.14 / 14. Mai 2018

ASSIGNEE:

QUATTRO VASCULAR PTE LTD

By: [Signature]
Name: Gim Moey Ong
Title: Director
Date: May 25, 2018

ACKNOWLEDGEMENT

State of California

County of Santa Clara

On May 25, 2018, before me, Kristine Orosz, the undersigned, a Notary Public for the state, personally appeared Gim Moey Ong, who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument, the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature [Signature]




Exhibit A

Identified Patents

Patent No.	Country	Filing Date	Application No.	Issue Date	Title
	US	October 14, 2011	61/547,448		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	PCT	October 11, 2012	PCT/EP2012/070142		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
9,415,140 B2	US	October 11, 2012	14/350,483	August 16, 2016	FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
EP2766062 B1	EU	October 11, 2012	EP20120778272	August 26, 2015	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
CN104039371B	China	October 11, 2012	CN201280061266	June 1, 2016	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
ES2550348 (T3)	Spain	October 11, 2012	ES12778272T	June 11, 2015	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	Japan	October 11, 2012	JP2014535073A		IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
	Singapore	October 11, 2012	11201401329V	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
IT 50 2015 0000 76755	Italy	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
GB 2 766 062	United Kingdom	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
FR 2 766 062	France	October 11, 2012	EP20120778272	granted	IMPROVED FORMULATIONS FOR DRUG-COATED MEDICAL DEVICES
DE 60 2012 010 093	Germany	October 11, 2012	EP20120778272	granted	VERBESSERTE FORMULIERUNGEN FÜR WIRKSTOFFBESCHICHTETE MEDIZINISCHE VORRICHTUNGEN

Ausdruck

Amtsgericht Charlottenburg
- Handelsregister Abteilung B -

HRB 83198 B

Aktueller Ausdruck

HRB 83198 B

Handelsregister Abteilung B
Amtsgericht Charlottenburg

1. Anzahl der bisherigen Eintragungen

4 Eintragung(en)

2.a) Firma

InnoRa Gesellschaft mbH

**b) Sitz, Niederlassung, inländische Geschäftsanschrift, empfangsberechtigte Person,
Zweigniederlassungen**

Berlin

Robert-Koch-Platz 4, 10115 Berlin

c) Gegenstand des Unternehmens

Die Einwerbung von wissenschaftlichen Drittmittelprojekten und privat finanzierten Forschungsaufträgen für die universitäre Radiologie sowie die Begleitung dieser Projekte und Forschungsaufträge; die Studienplanung, Produktentwicklung, Zulassung und Vermarktung von Hilfsmitteln für die diagnostische und therapeutische Radiologie und verwandte Anwendungen;
Erschließung von Quellen zur Finanzierung der genannten Aufgaben.

3. Grund- oder Stammkapital

27.000 EUR

4.a) Allgemeine Vertretungsregelung

Ist ein Geschäftsführer bestellt, so vertritt er die Gesellschaft allein. Sind mehrere Geschäftsführer bestellt, wird die Gesellschaft gemeinschaftlich durch zwei Geschäftsführer oder durch einen Geschäftsführer in Gemeinschaft mit einem Prokuristen vertreten. Einzelvertretungsbefugnis kann erteilt werden.

**b) Vorstand, Leitungsorgan, geschäftsführende Direktoren, persönlich haftende Gesellschafter,
Geschäftsführer, Vertretungsberechtigte und besondere Vertretungsbefugnis**

Geschäftsführer:

mit der Befugnis die Gesellschaft allein zu vertreten mit der Befugnis Rechtsgeschäfte mit sich selbst oder als Vertreter Dritter abzuschließen

Dr. Speck, Thomas, *16.06.1968, Berlin

6.a) Rechtsform, Beginn, Satzung oder Gesellschaftsvertrag

Gesellschaft mit beschränkter Haftung

Gesellschaftsvertrag vom: 12.11.2001

Zuletzt geändert am: 25.08.2005

7. Tag der letzten Eintragung

14.05.2018

Seite 1 von 2

- Wiedergabe des aktuellen Registerinhalts -
Abruf vom 14.05.2018, 17:04

Amtsgericht Charlottenburg
- Handelsregister Abteilung B -

HRB 83198 B

~~Ausdruck~~

09.01.2017

14.05.2018

Seite 2 von 2

Urkundenrolle Nr. 159 / 2018
des Notars Roland Schiller in Berlin

1.0

I hereby certify that this document was signed in my presence by

Mr. Dr. Thomas Speck, born on 1968.06.16,
resident Jänickestr. 99, 14167 Berlin,
personally known to me.

2.0

The Notary asked for any prior involvement within the meaning of Act 3
Para. 1 No. 7 German Notarisation Act. The question was answered in
the negative.

Berlin, 2018.08.14


Notar